Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Clinical trial NCT05215340 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05215340
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-04
- Primary completion
- 2030-03-04
- Enrollment
- 740
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.